Navigation Links
Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Date:9/3/2013

.30 miles west of Akron, and other related healthcare facilities and services. Community Health Systems stated that the parties will complete the due diligence process and work toward finalizing the terms of a definitive agreement. Wayne T. Smith, Chairman, President and CEO of CHS said, "The strategic alliance formed between Cleveland Clinic and Community Health Systems earlier this year is gaining momentum as we work together to advance high-quality, cost-effective healthcare services within our own organizations," The Full Research Report on Community Health Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7587_CYH]

Neurocrine Biosciences, Inc. Research Report  

On August 29, 2013, Neurocrine Biosciences Inc. (Neurocrine Biosciences) announced that in accordance to the Company's collaboration with AbbVie for elagolix in 2010, the latter has initiated the second Phase III pivotal trial to evaluate elagolix for the treatment of endometriosis. Neurocrine Biosciences informed that the second Phase III trial is a 24-week, multinational, randomized double-blind placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 788 women, age 18-49, with moderate-to-severe endometriosis-associated pain. The Company expects to provide top-line data from the second Phase III trial in Q3 2014 and complete in 2015. The Full Research Report on Neurocrine Biosciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8228_NBIX]

Alnylam Pharmaceuticals Inc. Research Report<
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
2. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
3. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
4. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
5. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
8. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
9. Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
10. Sanarias Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
11. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ... IBD biology, human genetics, genomic technology, and drug ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ... clinical and aesthetic dermatology practitioners in the 21 st ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, ... and technologies must be able to protect ... (IP). (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ... nature of the Medical Device Industry, it ... industry sectors of cases involving IP infringement. ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Conseco, Inc. (NYSE:,CNO) announced that Todd M. Hacker is ... president and treasurer. He will report to Ed,Bonach, Conseco,s ... Conseco from YRC Worldwide, where he was vice,president and ... From 2005-2006, he was senior vice president, finance and,administration, ...
... MCKINNEY, Texas, Jan. 8 Torchmark Corporation,(NYSE: TMK ... market,closes on Wednesday, February 6, 2008. In conjunction with ... listen to a,conference call that will be broadcast live ... a.m. Eastern. At that time a copy of the,Company,s ...
... HGR ) announced today that it plans to report ... on Monday, February 11,2008., The Company plans to issue ... 31, 2007 on Monday, February 11, 2008, after the,close of ... 9:00,a.m., EST, on Tuesday, February 12, 2008. Those wishing to ...
... LAKES, N.J., Jan. 8 Medco Health,Solutions, Inc. (NYSE: ... Jr. today,reiterated the company,s positive outlook for 2008 at ... The company reiterated its guidance for 2008 GAAP diluted ... assets that,existed when Medco became a publicly traded company, ...
... of developing breast cancer among people who carry the BRCA1 ... January 9/16 issue of JAMA. , BRCA1 and BRCA2 are ... magnitude of the risk of breast cancer in BRCA1 and ... options. The risk of breast cancer in BRCA1 and ...
... likely to undergo heart, liver and kidney transplantation , , TUESDAY, ... and rural areas are less likely to get organ transplants ... study found. , The study of almost 175,000 potential transplant ... percent to 15 percent less likely to be wait-listed and ...
Cached Medicine News:Health News:Torchmark Corporation Announces Fourth Quarter 2007 Earnings Release and Conference Call 2Health News:Hanger Orthopedic Group, Inc. Announces 2007 Year-End Earnings Release Conference Call 2Health News:Medco CEO Reiterates Guidance, Positive Outlook for 2008 2Health News:Breast cancer risk varies significantly among BRCA1 and BRCA2 carriers 2Health News:Rural Residents Get Fewer Organ Transplants: Study 2Health News:Rural Residents Get Fewer Organ Transplants: Study 3
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: